Clinical Trial Update: Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD [Phase 4]

View source ↗

Summary

Phase 4 trial investigating cardiac effects of Spiolto/Respimat in patients with COPD was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Respimat
• Spiolto (tiotropium/olodaterol)

Snippet

Sponsor: RWTH Aachen University | Conditions: COPD | Phase 4 | Status: WITHDRAWN